Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GeneDx Holdings Corp. (WGS)

GeneDx Q1 revenue rises 17% to $102.3 million; 2026 revenue guidance cut

Mixed Impact 4 of 5 guidance Written later

GeneDx reported first-quarter 2026 revenue of $102.3 million, up 17% year over year, but lowered its full-year 2026 revenue guidance to $475 million to $490 million from $540 million to $555 million. The company also reported a GAAP net loss of $63.3 million, including a $31.3 million impairment loss, which matters to shareholders because the revenue outlook has been reset and the quarter swung from a year-earlier adjusted profit to an adjusted loss.

Key points

  • Q1 2026 revenue was $102.3 million, up 17% from $87.1 million a year earlier; exome and genome test revenue rose 27% to $90.6 million.
  • Full-year 2026 revenue guidance was updated to $475 million to $490 million, down from the previous $540 million to $555 million.
  • GAAP net loss was $63.3 million, or $2.16 per share, including a $31.3 million impairment loss; adjusted net loss was $8.2 million versus adjusted net income of $9.2 million in Q1 2025.
  • Cash, cash equivalents, marketable securities and restricted cash totaled $171.7 million as of March 31, 2026.

The filing

CompanyGeneDx Holdings Corp. (WGS)
Form8-K, current report
Filed with the SECMay 4, 2026, 4:09 PM ET
Accession number0001818331-26-000039

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.